Haisco Pharmaceutical Group Co., Ltd.

SZSE:002653 Stock Report

Market Cap: CN¥34.1b

Haisco Pharmaceutical Group Past Earnings Performance

Past criteria checks 3/6

Haisco Pharmaceutical Group's earnings have been declining at an average annual rate of -13.2%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 2.2% per year. Haisco Pharmaceutical Group's return on equity is 13.1%, and it has net margins of 12.8%.

Key information

-13.2%

Earnings growth rate

-13.6%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-2.2%
Return on equity13.1%
Net Margin12.8%
Next Earnings Update12 Apr 2025

Recent past performance updates

Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations

Aug 22
Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations

Recent updates

Is Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) Trading At A 38% Discount?

Dec 19
Is Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) Trading At A 38% Discount?

Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) Shares May Have Run Too Fast Too Soon

Nov 19
Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) Shares May Have Run Too Fast Too Soon

Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations

Aug 22
Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations

With Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) It Looks Like You'll Get What You Pay For

Jul 25
With Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) It Looks Like You'll Get What You Pay For

Haisco Pharmaceutical Group (SZSE:002653) Has A Pretty Healthy Balance Sheet

Jul 04
Haisco Pharmaceutical Group (SZSE:002653) Has A Pretty Healthy Balance Sheet

Calculating The Fair Value Of Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

Jun 17
Calculating The Fair Value Of Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

These 4 Measures Indicate That Haisco Pharmaceutical Group (SZSE:002653) Is Using Debt Reasonably Well

Mar 19
These 4 Measures Indicate That Haisco Pharmaceutical Group (SZSE:002653) Is Using Debt Reasonably Well

Risks To Shareholder Returns Are Elevated At These Prices For Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

Feb 27
Risks To Shareholder Returns Are Elevated At These Prices For Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

Revenue & Expenses Breakdown

How Haisco Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:002653 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 243,7224761,645553
30 Jun 243,6723851,638522
31 Mar 243,4843581,566509
31 Dec 233,3552951,522517
30 Sep 233,3023751,585512
30 Jun 233,1382821,534477
31 Mar 233,0772801,509453
01 Jan 233,0152771,465448
30 Sep 222,9591731,403425
30 Jun 222,744951,325417
31 Mar 222,607841,256425
01 Jan 222,7733451,331431
30 Sep 212,8665091,355471
30 Jun 213,1547281,444486
31 Mar 213,4697961,626447
31 Dec 203,3306371,585406
30 Sep 203,3265131,707317
30 Jun 203,5204881,790259
31 Mar 203,6875721,875244
31 Dec 193,9374941,973235
30 Sep 194,3294131,887236
30 Jun 194,1054231,837229
31 Mar 193,7883231,630214
31 Dec 183,4273331,511204
30 Sep 182,6243371,320128
30 Jun 182,208247989184
31 Mar 182,0612541,024152
31 Dec 171,856238939119
30 Sep 171,8063351,02296
30 Jun 171,6063411,0200
31 Mar 171,5354448870
31 Dec 161,4364437770
30 Sep 161,3424065960
30 Jun 161,3263955880
31 Mar 161,1473154650
31 Dec 151,2123724520
30 Sep 151,1793724310
30 Jun 151,2334344210
31 Mar 151,2264694300
01 Jan 151,2114514350
30 Sep 141,1105203610
30 Jun 141,0675243240
31 Mar 141,0315202970

Quality Earnings: 002653 has a large one-off gain of CN¥116.9M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 002653's current net profit margins (12.8%) are higher than last year (11.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 002653's earnings have declined by 13.2% per year over the past 5 years.

Accelerating Growth: 002653's earnings growth over the past year (27.1%) exceeds its 5-year average (-13.2% per year).

Earnings vs Industry: 002653 earnings growth over the past year (27.1%) exceeded the Pharmaceuticals industry -2.5%.


Return on Equity

High ROE: 002653's Return on Equity (13.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 01:01
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Haisco Pharmaceutical Group Co., Ltd. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yue GaoChangjiang Securities Co. LTD.
Shanshan LiChina Merchants Securities Co. Ltd.
Sophia ZhangChina Stock Investment Research Co. Ltd. (GZ500..com)